Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85 CHF | -1.73% | -1.59% | +0.15% |
07:28am | Novartis reports positive interim results for Fabhalta | CF |
05:26am | Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial | MT |
Sales 2024 * | 48.16B 43.95B | Sales 2025 * | 49.98B 45.61B | Capitalization | 207B 189B |
---|---|---|---|---|---|
Net income 2024 * | 10.64B 9.71B | Net income 2025 * | 11.57B 10.56B | EV / Sales 2024 * | 4.56 x |
Net Debt 2024 * | 11.94B 10.9B | Net Debt 2025 * | 9.62B 8.78B | EV / Sales 2025 * | 4.34 x |
P/E ratio 2024 * |
18.5
x | P/E ratio 2025 * |
16.5
x | Employees | 76,057 |
Yield 2024 * |
3.81% | Yield 2025 * |
3.98% | Free-Float | 81.95% |
Latest transcript on Novartis AG
1 day | -1.84% | ||
1 week | -1.61% | ||
Current month | -2.74% | ||
1 month | -0.64% | ||
3 months | -8.43% | ||
6 months | -2.55% | ||
Current year | +0.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | - | |
5.57% | 18 M€ | +3.25% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-16 | 85 | -1.73% | 3 059 757 |
24-04-15 | 86.5 | +0.46% | 2,331,975 |
24-04-12 | 86.1 | +0.55% | 2,419,969 |
24-04-11 | 85.63 | -0.58% | 2,226,966 |
24-04-10 | 86.13 | -0.28% | 2,274,261 |
Delayed Quote Swiss Exchange, April 16, 2024 at 07:49 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.13% | 207B | |
+28.79% | 676B | |
+23.86% | 559B | |
-5.84% | 356B | |
+15.75% | 320B | |
+4.32% | 286B | |
+3.34% | 213B | |
-8.92% | 199B | |
-10.00% | 147B | |
-7.82% | 142B |
- Stock Market
- Equities
- NOVN Stock